Connection

WILLIAM DECKER to Humans

This is a "connection" page, showing publications WILLIAM DECKER has written about Humans.
Connection Strength

0.305
  1. Comprehensive normalization and binary classification methods for enhanced sensitivity and reproducibility in Luminex assay quantitation. J Immunol Methods. 2025 Mar; 538:113826.
    View in: PubMed
    Score: 0.027
  2. The mARS complex: a critical mediator of immune regulation and homeostasis. Front Immunol. 2024; 15:1423510.
    View in: PubMed
    Score: 0.025
  3. Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy. FASEB J. 2024 May 31; 38(10):e23644.
    View in: PubMed
    Score: 0.025
  4. CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential. Front Immunol. 2020; 11:613204.
    View in: PubMed
    Score: 0.020
  5. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types. Front Immunol. 2020; 11:608024.
    View in: PubMed
    Score: 0.020
  6. Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. Stem Cells Dev. 2016 05 15; 25(10):774-87.
    View in: PubMed
    Score: 0.014
  7. Stepping Out of the Cytosol: AIMp1/p43 Potentiates the Link Between Innate and Adaptive Immunity. Int Rev Immunol. 2015; 34(5):367-81.
    View in: PubMed
    Score: 0.014
  8. In This Issue: Cellular Stress and the Interface of Innate and Adaptive Immunity, and Other Topics. Int Rev Immunol. 2015; 34(5):365-6.
    View in: PubMed
    Score: 0.013
  9. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.
    View in: PubMed
    Score: 0.011
  10. Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease. Cytokine Growth Factor Rev. 2011 Aug; 22(4):177-87.
    View in: PubMed
    Score: 0.010
  11. Dendritic cell vaccines for the immunocompromised patient: prevention of influenza virus infection. Expert Rev Vaccines. 2010 Jul; 9(7):721-30.
    View in: PubMed
    Score: 0.010
  12. Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. Blood. 2009 Apr 30; 113(18):4213-23.
    View in: PubMed
    Score: 0.009
  13. Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells. J Immunother. 2008 Feb-Mar; 31(2):157-65.
    View in: PubMed
    Score: 0.008
  14. Progress in dendritic cell immunotherapy: elucidating the enigma of Th-1 polarization. Hum Vaccin. 2008 Mar-Apr; 4(2):162-4.
    View in: PubMed
    Score: 0.008
  15. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant. 2006 Feb; 12(2):113-25.
    View in: PubMed
    Score: 0.007
  16. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006 Apr 12; 24(16):3203-16.
    View in: PubMed
    Score: 0.007
  17. MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci Adv. 2025 Feb 14; 11(7):eads4227.
    View in: PubMed
    Score: 0.007
  18. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.005
  19. The tissue-specific, alternatively spliced single ATG exon of the type 3 voltage-dependent anion channel gene does not create a truncated protein isoform in vivo. Mol Genet Metab. 2000 May; 70(1):69-74.
    View in: PubMed
    Score: 0.005
  20. Revised fine mapping of the human voltage-dependent anion channel loci by radiation hybrid analysis. Mamm Genome. 1999 Oct; 10(10):1041-2.
    View in: PubMed
    Score: 0.005
  21. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017 04 13; 544(7649):250-254.
    View in: PubMed
    Score: 0.004
  22. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015 Dec; 35 Suppl:S276-S304.
    View in: PubMed
    Score: 0.004
  23. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis. 2015 Jun; 36 Suppl 1:S254-96.
    View in: PubMed
    Score: 0.003
  24. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015 Dec; 35 Suppl:S185-S198.
    View in: PubMed
    Score: 0.003
  25. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and S?zary syndrome. Clin Cancer Res. 2015 Jan 15; 21(2):274-85.
    View in: PubMed
    Score: 0.003
  26. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.003
  27. Modeling dendritic cell vaccination for influenza prophylaxis: potential applications for niche populations. J Infect Dis. 2013 Jun 01; 207(11):1764-72.
    View in: PubMed
    Score: 0.003
  28. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One. 2012; 7(12):e50830.
    View in: PubMed
    Score: 0.003
  29. Ex?vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R?(null) mice. Exp Hematol. 2012 Jun; 40(6):445-56.
    View in: PubMed
    Score: 0.003
  30. Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One. 2012; 7(1):e30814.
    View in: PubMed
    Score: 0.003
  31. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9.
    View in: PubMed
    Score: 0.003
  32. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother. 2010 Sep; 33(7):684-96.
    View in: PubMed
    Score: 0.002
  33. Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells. Stem Cells. 2009 Aug; 27(8):1932-40.
    View in: PubMed
    Score: 0.002
  34. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
    View in: PubMed
    Score: 0.002
  35. De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine. 2009 Mar 04; 27(10):1479-84.
    View in: PubMed
    Score: 0.002
  36. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol. 2008 Nov; 128(11):2631-2639.
    View in: PubMed
    Score: 0.002
  37. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant. 2006 Mar; 37(6):575-82.
    View in: PubMed
    Score: 0.002
  38. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006 Feb; 37(4):359-66.
    View in: PubMed
    Score: 0.002
  39. AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy. 2006; 8(2):95-104.
    View in: PubMed
    Score: 0.002
  40. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
    View in: PubMed
    Score: 0.002
  41. Retrotransposition of glycerol kinase-related genes from the X chromosome to autosomes: functional and evolutionary aspects. Genomics. 1999 Aug 01; 59(3):282-90.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.